This page shows what was measured, who it was measured in, and what that does not settle.
What Paclitaxel does in the body
Advanced carcinoma of the ovary
From the FDA-approved label: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · P88XT4IS4D · read 2026-08-29
Its recorded molecular formula is C47H51NO14, weighing 853.91.
US prescribing information · a1a06de1-d9a4-460a-b87d-5e40305b065c · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 92 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
✗ The study did not show it
Who was studied
NCT00977938
How many people
25682
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Disease-Free Survival (DFS) at the Primary Analysis
✗ The study did not show it
Who was studied
NCT00490139
How many people
8381
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105
✗ The study did not show it
Who was studied
NCT02194738
How many people
8300
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Rate of TAXUS stent related cardiac events as classified by the Clinical Events Committee (CEC).
✗ The study did not show it
Who was studied
NCT00569751
How many people
5016
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry.
✗ The study did not show it
Who was studied
NCT01042379
How many people
5000
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Invasive Disease-free Survival (IDFS) Rate at 5 Years
✗ The study did not show it
Who was studied
NCT00433511
How many people
4994
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin. Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness in pediatric patients have not been established.”
US prescribing information · a1a06de1-d9a4-460a-b87d-5e40305b065c · read 2026-08-30
On older people, the label states: “Of the 229 patients in the randomized study who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) for the treatment of metastatic breast cancer, 13% were at least 65 years of age and < 2% were 75 years or older.”
US prescribing information · a1a06de1-d9a4-460a-b87d-5e40305b065c · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on its mechanism of action and findings in animals, paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] .”
US prescribing information · a1a06de1-d9a4-460a-b87d-5e40305b065c · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of paclitaxel in human milk, or its effect on the breastfed child or on milk production.”
US prescribing information · a1a06de1-d9a4-460a-b87d-5e40305b065c · read 2026-08-30
On people with reduced liver function, the label states: “No adjustment of the starting paclitaxel protein-bound particles for injectable suspension (albumin-bound) dose is required for patients with mild hepatic impairment (total bilirubin > ULN and ≤ 1.5 x ULN and aspartate aminotransferase [AST] ≤ 10 x ULN).”
US prescribing information · a1a06de1-d9a4-460a-b87d-5e40305b065c · read 2026-08-30
On people with reduced kidney function, the label states: “No adjustment of the starting paclitaxel protein-bound particles for injectable suspension (albumin-bound) dose is required for patients with mild to moderate renal impairment (estimated creatinine clearance 30 to <90 mL/min) [see Clinical Pharmacology (12.3) ].”
US prescribing information · a1a06de1-d9a4-460a-b87d-5e40305b065c · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Injection
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4, S6.
No source is stored against this line.
What is in the pack
Sold as injectable, powder, injection, solution, injection, given by the injection, intravenous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Injection
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
66 products list this as an active ingredient in the United States drug directory. 66 of them contain it and nothing else.
FDA National Drug Code directory · 72205-063 · read 2026-08-29
They are sold as injection, injection, powder, for solution, injection, powder, lyophilized, for suspension, injection, solution, injection, solution, concentrate and powder, taken intravenous.
FDA National Drug Code directory · 72205-063 · read 2026-08-29
The regulator's established pharmacologic class for it is microtubule inhibition [pe] and microtubule inhibitor [epc].
FDA National Drug Code directory · 72205-063 · read 2026-08-29
26 published labels name it as an active ingredient. 26 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · fec9ddee-53a9-4a61-ad0a-be6b604de084 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · fec9ddee-53a9-4a61-ad0a-be6b604de084 · read 2026-08-29
PACLITAXEL is intravenous at 3 DOSAGE FORMS AND STRENGTHS For injectable suspension, for intravenous use: white to yellow, sterile lyophilized powder or cake containing 100 mg of paclitaxel formulated as albumin-bound particles in single-dose vial…, recorded as fda label in effect 2026-05-15 in the United States.
US prescribing information · a1a06de1-d9a4-460a-b87d-5e40305b065c · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Paclitaxel studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
24 documents were read for this substance.
RNAWiki source record
9 of them state the same halfLife, and they agree.
RNAWiki source record
9 of them state the same proteinBinding, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
P88XT4IS4D
RxNorm concept
312199
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4, S6.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
24 approved applications cover products containing this substance. The earliest was NDA020262, approved 19921229 to HQ SPCLT PHARMA.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
Q2
On the Paclitaxel label: indicated for what?
"Paclitaxel is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.": indications and usage on Paclitaxel's label. DailyMed label · 135502ff-002c-4a29-ba93-60855cf44f31 · 2026-08-10
Q3
2366 registered trials of Paclitaxel — at which phases?
Registered studies posting no result
1660 of 2366
2366 registered studies of Paclitaxel: 1343 phase2, 635 phase1, 572 phase3, 39 na, 37 na or unstated, 23 phase4, 12 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
terminated; "no participants enrolled in a three year period"
NCT00003622
withdrawn; "No recruitment"
NCT00003852
terminated; "lack of patient inclusion"
NCT00004093
terminated; "Original Principal Investigator left the institution."
NCT00004859
terminated; "Trial was stopped early for futility"
14 further recorded trials
NCT00005612
terminated; "Low accrual"
NCT00006374
withdrawn; "Slow accrual"
NCT00016276
terminated; "Administratively complete."
NCT00022230
withdrawn; "PI left Institution"
NCT00022633
terminated; "Permanently Closed Due to Poor Accrual"
NCT00025298
terminated; "low accrual"
NCT00031577
terminated; "Administrative closure 9/22/2006. Decline in enrollment at CHOP. due to competing protocols with new agents."
NCT00041470
terminated; "Sponsor withdrew the study"
NCT00042835
terminated; "Administratively complete."
NCT00048893
terminated; "The study was closed to accrual due to very poor enrollment."
NCT00054392
withdrawn; "Not opened at Fox Chase Cancer Center"
NCT00055887
withdrawn; "Study never started. No patients were enrolled."
NCT00057928
withdrawn; "lack of accrual"
NCT00063258
terminated; "Low accrual rate"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Paclitaxel used paclitaxel (Taxol®, 6 mg/mL, Bristol-Myers Squibb Pharmaceutical Group) — over how long?
studies of Paclitaxel used the recorded amount. ClinicalTrials.gov · 2026-09-01
9 recorded entries; human; IV; also "paclitaxel (Taxol®, 6 mg/mL, Bristol-Myers Squibb Pharmaceutical Group)", "Paclitaxel (80 mg/m^2) was administered by IV infusion over 1 hour following administration of FAR.", "Paclitaxel 200mg/m2"
IV; Paclitaxel (80 mg/m^2) was administered by IV infusion over 1 hour following administration of FAR.
NCT03081689
Paclitaxel 200mg/m2
NCT05244837
Paclitaxel 175mg/m2
NCT05244837
Nab-paclitaxel 260 mg/m2
NCT07602907
Paclitaxel Oral Solution (50mg/qd)
3 more recorded rows
humanNCT07602907
Paclitaxel Oral Solution (100mg/TIW)
humanNCT07602907
Paclitaxel Oral Solution (150mg/TIW)
humanNCT07602907
Paclitaxel Oral Solution (200mg/TIW)
recorded 2026-09-01 · last checked 2026-09-04
Q6
Paclitaxel's half-life is 13 to 27 hours — which schedules were studied?
13 to 27 hours, the half-life Paclitaxel's label states: "Elimination At the clinical dose range of 80 to 300 mg/m 2 (0.31 to 1.15 times the maximum approved recommended dosage), the mean total clearance of paclitaxel ranges from 13 to 30 L/h/m 2 and the mean terminal half-life ranges from 13 to 27 hours." DailyMed label · 135502ff-002c-4a29-ba93-60855cf44f31 · 2026-08-10
Show the evidence
half lifepharmacokinetics
13 to 27 hours; Elimination At the clinical dose range of 80 to 300 mg/m 2 (0.31 to 1.15 times the maximum approved recommended dosage), the mean total clearance of paclitaxel ranges from 13 to 30 L/h/m 2 and the mean terminal half-life ranges from 13 to 27 hours.
metabolismpharmacokinetics
Metabolism In vitro studies with human liver microsomes and tissue slices showed that paclitaxel in Paclitaxel protein-bound particles for injectable suspension (albumin-bound) was metabolized primarily to 6α-hydroxypaclitaxel by CYP2C8; and to two minor metabolites, 3'‑ p ‑hydroxypaclitaxel and 6α, 3'- p -dihydroxypaclitaxel, by CYP3A4.
recorded 2026-08-10 · last checked 2026-09-04
Q7
Which running trial of Paclitaxel could settle lifespan?
NCT04921527 measures progression-free survival (PFS), reading out 2025-07-31.
209 open trials; n 454; "Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer"
Show the evidence
Trial
NCT04921527
"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer"; n 454; "progression-free survival (PFS)"; 2025-07-31
NCT02299999
"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer"; n 1460; "Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm"; 2025-12
NCT04982237
"A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer"; n 445; "progression-free survival (PFS) assessed by blinded independent central review (BICR) per RECIST v1.1"; 2025-12-30
NCT03997123
"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC"; n 923; "Overall Survival (OS)"; 2026-03-16
NCT04660760
"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer"; n 116; "Progression-free survival"; 2026-05-31
NCT05781308
"Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy"; n 156; "Progression Free Survival at 6 months determined by independent reviewer"; 2026-06
14 further recorded trials
NCT04494425
"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer"; n 866; "Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population"; 2026-06-19
NCT06038578
"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer"; n 146; "Progression free Survival (PFS)"; 2026-06-30
NCT06279364
"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer"; n 524; "Overall Survival (OS)"; 2026-07
NCT01167712
"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer"; n 692; "Progression-Free Survival"; 2026-07-02
NCT03734029
"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]"; n 557; "Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer"; 2026-08-01
NCT07441486
"A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer"; n 50; "Progression-Free Survival (PFS)"; 2026-08-30
NCT04704934
"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)"; n 490; "Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel"; 2026-08-31
NCT03085056
"Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer"; n 13; "Progression-Free Survival (PFS)"; 2026-09
NCT04342910
"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC"; n 550; "Overall Survival (OS) in PD-L1 Positive Participants."; 2026-09-01
NCT04634877
"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)"; n 990; "Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence"; 2026-09-15
NCT03914612
"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer"; n 813; "Progression-free Survival (PFS)"; 2026-09-26
NCT04892953
"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy"; n 51; "Progression free survival (PFS)"; 2026-09-30
NCT05095467
"HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction"; n 157; "3-year Overall Survival, OS"; 2026-10
NCT06346392
"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2"; n 594; "Progression Free Survival (PFS) in all randomized participants"; 2026-10-14
Q8
Which 567 trials of Paclitaxel posted no result?
Posted no result
567 of 567 completed trials
Registrations
NCT00003582, NCT00003072, NCT00002519, NCT00003050, NCT00003214 and NCT00001272, and 561 more
Completion dates
oldest 1996-12; newest 2024-08-16
Show the evidence
Trial
NCT00003582
1996-12
NCT00003072
1998-10
NCT00002519
2000-01
NCT00003050
2000-03
NCT00003214
2000-04
NCT00001272
2000-05
14 further recorded trials
NCT00001450
2000-06
NCT00001499
2000-06
NCT00001387
2000-07
NCT00003230
2000-07
NCT00004979
2000-09
NCT00002711
2000-10
NCT00001498
2000-12
NCT00002587
2000-12
NCT00003877
2000-12
NCT00004057
2000-12
NCT00001383
2001-01
NCT00001384
2001-02
NCT00003413
2001-02
NCT00002949
2001-05
Q9
At the median, Paclitaxel's trials enrolled 70 people — anything larger?
Median enrolment
70
Largest enrolment
219483
Registered trials counted
2269
Q10
What do 24413 spontaneous reports say about Paclitaxel — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Paclitaxel appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 24413 reaction mentions were counted: diarrhoea 4671; neutropenia 3655; anaemia 3073; febrile neutropenia 2797. FAERS via Open Targets · CHEMBL428647 · 2026-06-24
Show the evidence
diarrhoea
4671
neutropenia
3655
anaemia
3073
febrile neutropenia
2797
neuropathy peripheral
2045
malignant neoplasm progression
1825
4 more recorded rows
thrombocytopenia
1709
dehydration
1619
disease progression
1602
leukopenia
1417
recorded 2026-06-24 · last checked 2026-09-04
Q11
Which 10 reactions does Paclitaxel's label not list?
The metabolism of paclitaxel is catalyzed by CYP2C8 and CYP3A4.
drug_interactions
Caution should be exercised when administering paclitaxel protein-bound particles for injectable suspension (albumin-bound) concomitantly with medicines known to inhibit or induce either CYP2C8 or CYP3A4.
drug_interactions
Use caution when concomitantly administering paclitaxel protein-bound particles for injectable suspension (albumin-bound) with inhibitors or inducers of either CYP2C8 or CYP3A4.
pharmacokinetics
Metabolism In vitro studies with human liver microsomes and tissue slices showed that paclitaxel in Paclitaxel protein-bound particles for injectable suspension (albumin-bound) was metabolized primarily to 6α-hydroxypaclitaxel by CYP2C8; and to two minor metabolites, 3'‑ p ‑hydroxypaclitaxel and 6α, 3'- p -dihydroxypaclitaxel, by CYP3A4.
pharmacokinetics
Testosterone, 17α-ethinyl estradiol, retinoic acid, and quercetin, a specific inhibitor of CYP2C8, also inhibited the formation of 6α-hydroxypaclitaxel in vitro .
pharmacokinetics
The pharmacokinetics of paclitaxel may also be altered in vivo as a result of interactions with compounds that are substrates, inducers, or inhibitors of CYP2C8 and/or CYP3A4 [see Drug Interactions ( 7 )] .
2 more recorded rows
Interaction statementclinical_pharmacology
Metabolism In vitro studies with human liver microsomes and tissue slices showed that paclitaxel in Paclitaxel protein-bound particles for injectable suspension (albumin-bound) was metabolized primarily to 6α-hydroxypaclitaxel by CYP2C8; and to two minor metabolites, 3'‑ p ‑hydroxypaclitaxel and 6α, 3'- p -dihydroxypaclitaxel, by CYP3A4.
Interaction statementclinical_pharmacology
Testosterone, 17α-ethinyl estradiol, retinoic acid, and quercetin, a specific inhibitor of CYP2C8, also inhibited the formation of 6α-hydroxypaclitaxel in vitro .
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.